Fibrinogen and fibrin clot structure in diabetes

被引:12
|
作者
Dunn, EJ [1 ]
Ariëns, RAS [1 ]
机构
[1] Univ Leeds, Sch Med, Acad Unit Mol Vasc Med, Leeds LS2 9JT, W Yorkshire, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
fibrinogen; diabetes; glycation; clot; lysis;
D O I
10.1007/s00059-004-2607-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is associated with an increased risk of developing cardiovascular disease, which is not fully accounted for by the accumulation of classic cardiovascular risk factors in patients. Recent evidence has demonstrated fibrinogen to be a powerful independent risk marker for cardiovascular disease in the general population, and it is also likely to contribute toward the increased atherosclerotic risk in diabetes. The etiology of hyperfibrinogenemia in diabetes is likely to be multifactorial, and at present the mechanisms involved have not been clarified. However, insulin, insulin resistance and inflammation are likely to be involved, especially in type 2 diabetes. The influence of diabetes in determining an individual's atherothrombotic risk is likely to extend beyond that of elevated fibrinogen levels, and may also act via changes in the structure and function of the fibrin clot that forms. Further research is needed to determine the mechanisms underlying these changes, which may lead to development of future interventions to reduce the excessive vascular risk associated with this disease.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 50 条
  • [21] The impact of fibrinogen carbamylation on fibrin clot formation and the inflammatory response
    Binder, Veronika
    Scavenius, Carsten
    Marti, Hans-Peter
    Roberts, Helen M.
    Chapple, Iain L. C.
    Jonsson, Roland
    Spriet, Endy
    Nyhaug, Anne Karin
    Mydel, Piotr
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2016, 83 (05) : 364 - 364
  • [22] The ultrastructure of fibrinogen-420 and the fibrin-420 clot
    Mosesson, MW
    Di Orio, JP
    Hernandez, I
    Hainfeld, JF
    Wall, JS
    Grieninger, G
    BIOPHYSICAL CHEMISTRY, 2004, 112 (2-3) : 209 - 214
  • [23] THE MOLECULAR-STRUCTURE OF FIBRINOGEN AND THE ARCHITECTURE OF THE FIBRIN CLOT - A MODEL FROM ELECTRON-MICROSCOPY
    WEISEL, JW
    PHILLIPS, GN
    STAUFFACHER, CV
    FORD, E
    COHEN, C
    THROMBOSIS AND HAEMOSTASIS, 1981, 46 (01) : 160 - 160
  • [24] EFFECT OF FIBRIN AND FIBRINOGEN PROTEOLYSIS PRODUCTS ON CLOT PHYSICAL PROPERTIES
    HIRSH, J
    FLETCHER, AP
    SHERRY, S
    AMERICAN JOURNAL OF PHYSIOLOGY, 1965, 209 (02): : 415 - &
  • [25] EFFECTS OF HYDROXYETHYL STARCH ON FIBRINOGEN, FIBRIN CLOT FORMATION, AND FIBRINOLYSIS
    STRAUSS, RG
    STUMP, DC
    HENRIKSEN, RA
    SAUNDERS, R
    TRANSFUSION, 1985, 25 (03) : 230 - 234
  • [26] STRUCTURE OF FIBRINOGEN AND DEGRADATION PRODUCTS OF FIBRINOGEN AND FIBRIN
    GAFFNEY, PJ
    BRITISH MEDICAL BULLETIN, 1977, 33 (03) : 245 - 252
  • [27] Glycemic control is of major importance for fibrin clot structure in type 1 diabetes
    Antovic, A.
    Mobarrez, F.
    Tehrani, S.
    Lins, P.
    Adamson, U.
    Wallen, N.
    Jorneskog, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 295 - 295
  • [28] Fibrinogen and fibrin structure and functions
    Mosesson, MW
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (08) : 1894 - 1904
  • [29] Fibrin Clot Structure in Type 1 Diabetes: No Gender Differences but Relations to Microangiopathy
    Tehrani, Sara
    Jorneskog, Gun
    Agren, Anna
    Lins, Per-Eric
    Wallen, Hakan
    Antovic, Aleksandra
    DIABETES, 2013, 62 : A107 - A107
  • [30] Gender aspects of fibrin clot structure in patients with type 1 diabetes mellitus
    Tehrani, S.
    Wallen, N. H.
    Elgue, G.
    Majeed, K.
    Henriksson, P.
    Agren, A.
    Adamson, U.
    Lins, P. -E.
    Jorneskog, G.
    Antovic, A.
    THROMBOSIS RESEARCH, 2013, 131 : S72 - S72